Introduction
============

Cancer is a complex genetic disease involving structural and expression abnormalities of both coding and non-coding genes. The search for cancer causing genes has identified two major classes namely the oncogenes and tumor suppressor genes (TSGs). Activation or over expression of a proto-oncogene, such as *cMyc*,[@b1-cin-11-2012-157] or inactivation of a tumor suppressor, such as *TP53*,[@b2-cin-11-2012-157],[@b3-cin-11-2012-157] causes tumorigenicity. Oncogene activation in tumors is straightforward, while the inactivation of TSGs is a complex process attained by different means including mutations, deletions, down regulation by microRNAs, epigenetic silencing etc. Although complete loss of TSG is common in tumors, recent studies indicate that a partial compromise in TSG function termed 'haploinsufficiency' contributes to the development and progression of many cancers.[@b4-cin-11-2012-157] The condition where one functional allele of a gene is lost by mutation or deletion, and the remaining normal allele is insufficient to execute its original physiological function, is called haploinsufficiency. This phenomenon is extensively applicable to TSGs[@b5-cin-11-2012-157] as they offer a benefit for cancer cells in regards to proliferation,[@b6-cin-11-2012-157] survival,[@b7-cin-11-2012-157] and metastasis.[@b8-cin-11-2012-157]

In principle, haploinsufficient TSGs are impaired by a 50% reduction in expression or activity. However, *in vivo* studies demonstrate that even a subtle 20% reduction of *PTEN* protein level---termed as 'quasi-insufficiency'--- could contribute to the development of cancer.[@b9-cin-11-2012-157] Another example is that *TP53*, when targeted by short hairpin RNAs (shRNAs), is shown to elicit distinct phenotypes ranging from hyperplasia to malignancy in mouse models depending on the reduction in its protein level.[@b10-cin-11-2012-157] This proves that some TSGs, like *PTEN*, are exquisitely sensitive to dose, while some, like *TP53*, are intermediately sensitive. Based on such observations, Berger et al has proposed a continuum model that accounts for subtle dosage effects of tumor suppressors including their regulation by microRNAs.[@b11-cin-11-2012-157] The dosage and function of haploinsufficient genes are critical, and understanding the impact of haploinsufficiency is important for assessment of interindividual genetic variation, as well as the molecular basis of haploinsufficiency disorders.

Haploinsufficiency of multiple genes cooperate to promote tumorigenesis, a phenomenon called 'compound haploinsufficiency'. The 5q deletion syndrome (5q-) is a paradigm of compound haploinsufficiency and demonstrates the importance of combinatorial interactions to elicit specific phenotypes.[@b12-cin-11-2012-157] Experimental evidence has shown that co-suppression of linked 8p TSGs promotes tumor formation more potently than any individual gene.[@b13-cin-11-2012-157] All the available evidence indicates that the functioning of a cell depends on the appropriate expression levels of proteins and, more importantly, that cell signalling pathways involve complex interactions between many proteins. Not only genes, but also microRNAs (miRNAs), a class of small noncoding RNAs, are shown to be haploinsufficient and to cause developmental abnormalities in humans.[@b14-cin-11-2012-157] In addition, genes involved in miRNA biosynthesis pathway, such as *DICER1*, *TARBP2* and *XPO5*, are identified as haploinsufficient tumor suppressors.[@b15-cin-11-2012-157]--[@b17-cin-11-2012-157]

miRNAs act at the post-transcriptional level of gene regulation through RNA-induced silencing complex (RISC) mediated translational inhibition or mRNA cleavage. The miRNA target recognition is mediated through the sequence complementarity between the 2--8 nt at the 5′ end of miRNA (seed sequence) and the 3′-UTR of target mRNA.[@b18-cin-11-2012-157] Based on the degree of complementarity, the mRNA is either guided for inhibition of translation or degradation resulting in the decrease of protein encoded by the target messenger.[@b19-cin-11-2012-157] This has extended the dimensions of haploinsufficiency as miRNAs can lead to the production of insufficient amount of proteins. Bioinformatics prediction and experimental analysis suggested that miRNAs can regulate approximately half of the mammalian genes, with a significant number of important oncogenes and tumor suppressor genes involved.[@b20-cin-11-2012-157],[@b21-cin-11-2012-157] A recent genome-wide association study has suggested that a gene with more than two miRNA target sites will have higher variability of expression than a gene which is not regulated by a miRNA. The variability is further increased by SNPs in the miRNA target sites.[@b22-cin-11-2012-157] Polymorphisms in the miRNA regulatory pathway are a novel class of functional polymorphisms present in the human genome. The initial demonstration that miRNA binding site variations can result in a phenotype was provided by Abelson et al who identified a mutation in the miR-189 binding site of *SLITRK1* and its association with Tourette's syndrome.[@b23-cin-11-2012-157] A pioneering study conducted by Carlo Croce's group showed that a germline mutation in pri-miR-16-1 resulted in low levels of miR-16-1 expression in familial chronic lymphocytic leukemia,[@b24-cin-11-2012-157],[@b25-cin-11-2012-157] providing evidence that sequence variation in miRNA genes may affect function and result in cancer susceptibility. Pre- and pri-miRNA SNPs in miR-124-1, miR-146a, miR-196-a2, miR-218, miR-219-1, miR-26a-1, miR-27a, miR-423, miR-492, and miR-499 have already been shown to increase/decrease cancer risk in various populations.[@b26-cin-11-2012-157]

Single nucleotide polymorphisms (SNPs) are single base pair changes in DNA that occur with a frequency of about 1 in 12,500 bp in the genome.[@b27-cin-11-2012-157] Several studies have shown that SNPs in microRNA networks moderately increase the risk of cancer incidence.[@b28-cin-11-2012-157] In general, sequence variations in pri-miRNAs, premiRNAs, mature miRNAs, and microRNA binding sites potentially affects the processing and/or target selection of miRNAs. As a consequence, aberrant expression of hundreds of genes and pathways greatly affecting miRNA function may occur.[@b29-cin-11-2012-157] SNPs in mature miRNAs and miRNA binding sites function analogously to modulate the miRNA-mRNA interaction and create or destroy miRNA binding sites. Supporting this idea, SNPs within the miRNA binding sites of genes have been implicated in susceptibility to various types of cancer.[@b30-cin-11-2012-157]--[@b33-cin-11-2012-157] Additionally, functional support for individual miR-SNPs implicated in cancer do exist.

In this study we analyzed the role of SNPs that occur at miRNA binding sites and miR-SNPs and their contribution towards haploinsufficiency of tumor suppressor genes.

Materials and Methods
=====================

Datasets
--------

A total of 110 haploinsufficient genes known to have a role in tumor initiation and progression were considered for the study. Among the total list, 63 tumorigenic haploinsufficient genes were obtained from Dang et al, 2008[@b34-cin-11-2012-157] while the remaining 47 genes were compiled using keyword search in PubMed and Online Mendelian Inheritance in Man (OMIM) database. For a comprehensive list of the haploinsufficient tumorigenic genes included in this study with their corresponding reference, see [Supplement 1](#s1-cin-11-2012-157){ref-type="supplementary-material"}.

Analysis of 3′UTR polymorphisms in mRNA targets and miR seed
------------------------------------------------------------

The haploinsufficient genes were analyzed for polymorphisms in their 3′UTR by submitting the respective gene ID in 'Polymorphism in microRNA Target Site' (PolymiRTS) database,[@b35-cin-11-2012-157] <http://compbio.uthsc.edu/miRSNP/>, designed to identify SNPs that disrupt the regulation of gene expression by miRNAs in human and mouse (last accessed on June 7th, 2012). The database is organized to provide links between SNPs in miRNA target sites, cis-acting expression quantitative trait loci (eQTLs), and the results of genome-wide association studies (GWAS) of human diseases. We applied filters to identify only the SNPs in the 3′UTR that were known to create binding sites for miRNAs and SNPs occurring in the seed region of miRNA themselves.

Classification and validation of SNPs obtained from polymiRTS
-------------------------------------------------------------

The SNPs predicted by the polymiRTS database were classified based on their effect into the following categories: (i) SNPs that lead to the creation of miRNA binding sites in the mRNA, (ii) SNPs that disrupted the originally existing miRNA binding sites and also resulted in creation of new miRNA binding sites in the mRNA, and (iii) miR-SNPs that altered the binding specificity of miRNAs. After classification, the SNPs were verified by submitting their rs ID in the NCBI's dbSNP Short genetic variation database <http://www.ncbi.nlm.nih.gov/projects/SNP/using> the batch query option. The output was downloaded in BED format and analyzed. Among the total 158 SNPs submitted, 156 SNPs were validated by dbSNP while 2 miR-SNPs (rs116596918 and rs116838571) were found to be new entries and validated by microRNA-related Single Nucleotide Polymorphism database (<http://www.bioguo.org/miRNASNP/miRNA_details.php>).[@b36-cin-11-2012-157]

Functional network prediction using GeneMANIA Cytoscape plug-in
---------------------------------------------------------------

To identify the functional significance, GeneMANIA Cytoscape plug-in which employs the GeneMANIA algorithm[@b37-cin-11-2012-157],[@b38-cin-11-2012-157] was utilized with default settings to plot the interactions among the haploinsufficient TSGs. The complete list of tumorigenic haploinsufficient genes were uploaded to Cytoscape[@b39-cin-11-2012-157] using GeneMANIA plug-in (<http://www.genemania.org/plugin/>). Further, only the genes that were found to have SNPs in their miRNA binding sites and those that are non-specifically targeted by miRNAs harboring miR-SNPs were uploaded individually to study the interactions among this subgroup. The GeneMANIA Cytoscape plug-in integrates association networks from multiple sources into a single composite network using a conjugate gradient optimization algorithm. This algorithm produces networks from the data either directly (as in the case of protein or genetic interactions) or by using an in-house analysis pipeline to convert profiles to functional association networks.

Results and Discussion
======================

Polymorphisms in 3′UTR of mRNA
------------------------------

Our analysis of tumorigenic haploinsufficient genes for genetic variations in the 3′UTR showed that 26% (29 out of 110) of them had at least one 3′UTR SNP resulting in creation of new binding sites for miRNAs thereby bringing the respective mRNA variant under the control of more new miRNAs. In total, 129 SNPs were found to create binding sites for 234 miRNAs in 29 genes ([Table 1](#t1-cin-11-2012-157){ref-type="table"}). Altogether, these SNPs contribute to haploinsufficiency by bringing the polymorphic mRNA under the control of more new microRNAs thereby leading to translational repression or mRNA degradation. *PPARA*, a nuclear transcription factor and *KIF1B*, a kinesin implicated in neuronal and non-neuronal tumors was found to harbor 17 SNPs creating putative binding sites for many miRNAs. On the contrary, the SNP rs121912664 in *TP53* creates putative miRNA binding site for miRNA-302 family, miR-520 family, miR-372, and miR-373-3p. The cell adhesion molecule *CDH1*, an important gene in tumor invasion with frequent allelic loss in metastatic tumors, was found to have 5 different SNPs that create putative binding sites for new miRNAs thereby altering the repertoire of miRNAs controlling this gene. Even *RB1*, the classical TSG, was predicted to have 3 SNPs that may down regulate its expression. If one allele is already lost in tumors, the remaining allele having at least one of these SNPs may be targeted by miRNAs and thereby lead to complete loss of cellular function, as postulated by Knudson's "two-hit hypothesis."

Another 10 SNPs were found to bring 8 different genes under the control of additional new miRNAs due to the presence of the respective SNP ([Fig. 1](#f1-cin-11-2012-157){ref-type="fig"}). A single SNP can create miR binding site for several miRNAs as well as delete a miR binding site. For example, the SNP rs186304832 in the 3′UTR of *KIF1B* results in the loss of binding of 2 different microRNAs to the variant mRNA while 7 new microRNAs will be targeting this particular variant. This alters the miRNA mediated gene expression control resulting in aberrant regulation of expression. A gene that was previously under the control of one miRNA comes under the control of 3 different new miRNAs which leads to extensive translational repression resulting in protein haploinsufficiency as represented by the polymorphism rs1138533 in *CDH1*. This mechanism is totally new, since one allele is not lost due to mutation or deletion, as in the case of classical haploinsufficiency. Rather there is a decrease in the overall protein product. In homozygous state, this SNP may result in complete or partial reduction in the expression based on the ability of the repressing miRNA. However, in heterozygous state, the same SNP can lead to 50% or even subtler reduction in expression, which can explain 'quasi-insufficiency'.

Ours is the first study to identify the SNP and miRNA mediated control of tumor suppressor dose as well as highlighting the importance of genetic variations in cancer. This mechanism is in agreement with the continuum model for tumor suppression that is related to the level of expression or activity of the TSG rather than to the discrete step-by-step changes in gene copy number.[@b11-cin-11-2012-157]

Polymorphisms in microRNA seed sequence
---------------------------------------

In addition, SNPs that occur in the seed sequence of miRNAs can alter the binding specificity of these miRNAs resulting in the binding to new non-target mRNAs. We analyzed 19 such miR-SNPs that cause miRNAs to bind new haploinsufficient tumor suppressor genes ([Table 2](#t2-cin-11-2012-157){ref-type="table"}). The SNP rs4636784 occurring in the seed of hsa-miR-4305 alters the binding specificity, thereby enabling it to target 6 new haploinsufficient genes (*CDH1, KIF1B, SMAD4, DFFB, FOXP1*, and *PTEN*). This can contribute to compound haploinsufficiency, wherein multiple genes cooperate to cause a particular phenotype.[@b7-cin-11-2012-157],[@b13-cin-11-2012-157] Alteration in one miRNA can alter the entire set of genes under its control thereby providing an advantage for cancer initiation and progression. In addition, the acquisition of miR-SNPs in tumors is simple enough to deregulate many genes than the need for individual mutations in all of them. This mechanism of miR-SNP mediated down regulation can also be extended to the unexplained allelic loss of *KIF1B* in neuroblastomas, where the tumor suppressor was shown to have no mutations or promoter methylation.[@b40-cin-11-2012-157] Tumors not showing genetic alterations in the TSG, but with aberrant TSG levels due to miRNA misregulation, could behave like tumors with deletion or mutation of the gene. Importantly, mapping the interactions between miRNAs and TSGs could be useful for defining and predicting cancer susceptibility and therapeutic response.

Networks
--------

Although reports on haploinsufficient genes associated with cancer is limited, analysis of the existing data shows that at least one third of total haploinsufficient genes to be tumorigenic. Tumor suppressors often act as components of complex networks, the overall function of which can be impaired by genetic and epigenetic alterations.[@b41-cin-11-2012-157],[@b42-cin-11-2012-157] For this reason we analyzed whether the haploinsufficient tumor suppressor genes share a common pathway or fall in a common interacting or functional network. The GeneMANIA algorithm was utilized for this purpose, and results indicate that almost 99% of haploinsufficient genes have a strong interaction, either directly or indirectly. *SMAD5* was excluded from the list as it was not recognized by the algorithm. Co-expression, co-localization, physical and genetic interactions, pathway interactions, and other interactions that arise through shared structural domains were shown to exist between the queried genes ([Fig. 2](#f2-cin-11-2012-157){ref-type="fig"}). *SPRED1* was the only gene to fall out of this network however co-expression links it to the group. Apart from the queried list of genes, the algorithm identified several other genes to be a part of this network including *DROSHA, DFFA, MRE11A, TRAPPC2L, TERF2, CDK6, BUB1, WRN, CCNA2,* and *RAD51*. Interestingly, the haploinsufficient status of some of these genes has already been described in developmental abnormalities and other diseases,[@b43-cin-11-2012-157]--[@b45-cin-11-2012-157] while some others are shown to have a role in tumor formation and their haploinsufficient status is yet to be established.[@b46-cin-11-2012-157]

Next we tested whether the 39 genes with SNPs in miRNA binding sites or targeted by miRNAs with altered specificity due to miR-SNPs fall in to a particular network or pathway. Results of GeneMANIA networking analysis suggested strong interactions between these genes ([Fig. 3](#f3-cin-11-2012-157){ref-type="fig"}). DNA repair genes and cell cycle checkpoint genes were enriched in this network and any aberrations in their expression offers selective advantage for the tumors to acquire additional genomic changes or mutations. *DFFB* was linked by co-expression, while *DIRC2* was shown to be completely out of the group. The following genes were found to be a part of this network and to mediate interactions between the queried genes: *MRE11A, DFFA, CCNB1, POLQ, AP1B1, RAD51, CCNG1, NPM1, DDB*1, and *WRN*. The identification of the mRNA targets that mediate the actions of miRNAs in disease pathways can reveal previously unrecognized components that may serve as targets for more traditional drug development.

Conclusion
==========

With the expanding understanding of the roles of miRNAs in various cellular processes and diseases, this is the first report to discuss the role of miRNAs and its contribution towards tumor suppressor gene haploinsufficiency at the protein level via 3′UTR SNPs and miR-SNPs. Further, this could be an alternate means for attaining compound heterozygosity observed in several tumors and the mechanism is in complete agreement with the continuum model of tumor suppression.[@b11-cin-11-2012-157] Our data suggests that 26% of the tumorigenic haploinsufficient genes were brought under the control of new miRNAs due to 3′UTR SNPs. The identification of 10 SNPs that drive haploinsufficiency by bringing the polymorphic mRNA under the control of miRNAs, other than the miRNAs which are deleted, needs experimental validation in tumors. This alteration in the miRNA mediated gene regulation may cause predisposition to cancer initiation and progression.

Evidence for co-operative contribution of oncogenic mutations with tumor suppressor haploinsufficiency also exist.[@b47-cin-11-2012-157] The realization that miR-SNPs play central roles in the aberrant regulation of tumor suppressor genes has provided a new perspective on our understanding of pathophysiologic mechanisms. In addition, networking analysis reveals strong interactions between the haploinsufficient tumor suppressor genes. Any subtle alteration in this network of genes due to SNPs at the 3′UTR and miR-SNPs may contribute to pathogenesis. We suggest that at least a few among these SNPs and their effect on miRNA binding will aid in the diagnosis and/or prognosis of such type of cancers, if experimentally validated. While challenges remain in this regard, the pace of development in this field suggests that new discoveries are forthcoming.

Our approach has currently focused only on analyzing 3′UTRs, although a small subset of miRNAs can target 5′UTRs, coding regions, and gene promoters. miR-SNPs leading to non-specific binding of miRNAs to tumor suppressors may also result in the loss of binding to their original targets. If the target is an oncogene, it will be over expressed and will result in tumorigenesis. This has not been focused on in this study. Since the rules for miRNA binding to its target changes constantly,[@b48-cin-11-2012-157] the databases need constant updating. The 110 tumor suppressor genes chosen for our study were already proven to be haploinsufficient in several cancers through experimental evidence. This list may likely grow due to continuous identification of haploinsufficient tumor suppressors.

Supplementary Data
==================

###### 

List of Haploinsufficient genes known to be involved in tumorigenesis.

  Haploinsufficient genes                                                                                                                                                                                                                                                                                                                                                                                                                 References
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------
  ANX7, APC, ARF, ATM, BAG1, BECN1, BRCA1, BRCA2, BUBR1, CAMTA1, CAV1, CDKN1B, CDKN1C, CDKN2B, CSN5, CTCF, DFFB, DIRC2, EEF1E1, ETV6, FBXW7, FOXP1, H2 AX, INI1, INK4C, KLF6, LIG4, LIS1, LKB1, MEL-18, MYH, NHERF1, NKX3--1, NPM1, P53, PAX5, PLK4, PPARA, PPARG, PRKAR1 A, PTCH1, PTEN, RAD50, RASSF1 A, ROR2, RPRM, SAM68, SERCA2, SMAD5, SOCS1, SOX9, SPRED1, ST7, TGFB1, TP53BP2, TP73, TRAPPC2, TSC1, TSC2, VHL, WT1, WWOX, YWHAE   [@b59-cin-11-2012-157]
  ATR                                                                                                                                                                                                                                                                                                                                                                                                                                     [@b66-cin-11-2012-157]
  BIM (BCL2 L11)                                                                                                                                                                                                                                                                                                                                                                                                                          [@b65-cin-11-2012-157]
  BLM                                                                                                                                                                                                                                                                                                                                                                                                                                     [@b69-cin-11-2012-157]
  BUB3                                                                                                                                                                                                                                                                                                                                                                                                                                    [@b78-cin-11-2012-157]
  CDH1                                                                                                                                                                                                                                                                                                                                                                                                                                    [@b92-cin-11-2012-157]
  CDKN1 A                                                                                                                                                                                                                                                                                                                                                                                                                                 [@b76-cin-11-2012-157]
  CHK1 (CHEK1)                                                                                                                                                                                                                                                                                                                                                                                                                            [@b81-cin-11-2012-157]
  CLU                                                                                                                                                                                                                                                                                                                                                                                                                                     [@b57-cin-11-2012-157]
  CREBBP (CBP)                                                                                                                                                                                                                                                                                                                                                                                                                            [@b97-cin-11-2012-157], [@b95-cin-11-2012-157], [@b53-cin-11-2012-157]
  DDB2                                                                                                                                                                                                                                                                                                                                                                                                                                    [@b74-cin-11-2012-157]
  DGCR8                                                                                                                                                                                                                                                                                                                                                                                                                                   [@b90-cin-11-2012-157]
  DICER1                                                                                                                                                                                                                                                                                                                                                                                                                                  [@b80-cin-11-2012-157], [@b50-cin-11-2012-157], [@b89-cin-11-2012-157]
  DLL4                                                                                                                                                                                                                                                                                                                                                                                                                                    [@b67-cin-11-2012-157], [@b71-cin-11-2012-157]
  DMP1                                                                                                                                                                                                                                                                                                                                                                                                                                    [@b73-cin-11-2012-157], [@b99-cin-11-2012-157], [@b82-cin-11-2012-157]
  DOK2                                                                                                                                                                                                                                                                                                                                                                                                                                    [@b52-cin-11-2012-157]
  FBXO11                                                                                                                                                                                                                                                                                                                                                                                                                                  [@b62-cin-11-2012-157]
  FEN1                                                                                                                                                                                                                                                                                                                                                                                                                                    [@b79-cin-11-2012-157]
  IKZF1 (IKAROS)                                                                                                                                                                                                                                                                                                                                                                                                                          [@b87-cin-11-2012-157], [@b77-cin-11-2012-157], [@b100-cin-11-2012-157]
  KIF1Bβ                                                                                                                                                                                                                                                                                                                                                                                                                                  [@b88-cin-11-2012-157]
  KLF5                                                                                                                                                                                                                                                                                                                                                                                                                                    [@b58-cin-11-2012-157]
  MAD2 L1                                                                                                                                                                                                                                                                                                                                                                                                                                 [@b86-cin-11-2012-157]
  MDM2 and MDM4                                                                                                                                                                                                                                                                                                                                                                                                                           [@b98-cin-11-2012-157]
  MLH1                                                                                                                                                                                                                                                                                                                                                                                                                                    [@b96-cin-11-2012-157]
  MSH2                                                                                                                                                                                                                                                                                                                                                                                                                                    [@b60-cin-11-2012-157], [@b61-cin-11-2012-157], [@b54-cin-11-2012-157]
  MUS81                                                                                                                                                                                                                                                                                                                                                                                                                                   [@b84-cin-11-2012-157]
  NBN                                                                                                                                                                                                                                                                                                                                                                                                                                     [@b63-cin-11-2012-157]
  NF1                                                                                                                                                                                                                                                                                                                                                                                                                                     [@b75-cin-11-2012-157], [@b107-cin-11-2012-157]
  NF2                                                                                                                                                                                                                                                                                                                                                                                                                                     [@b83-cin-11-2012-157]
  PINX1                                                                                                                                                                                                                                                                                                                                                                                                                                   [@b106-cin-11-2012-157]
  RAD17                                                                                                                                                                                                                                                                                                                                                                                                                                   [@b56-cin-11-2012-157]
  RB1                                                                                                                                                                                                                                                                                                                                                                                                                                     [@b101-cin-11-2012-157], [@b105-cin-11-2012-157]
  Ribosomal proteins (RPL35, RPL37 A, RPS19 and RPS8)                                                                                                                                                                                                                                                                                                                                                                                     [@b49-cin-11-2012-157]
  RPS14                                                                                                                                                                                                                                                                                                                                                                                                                                   [@b64-cin-11-2012-157], [@b51-cin-11-2012-157]
  RUNX1                                                                                                                                                                                                                                                                                                                                                                                                                                   [@b93-cin-11-2012-157]
  RXRA                                                                                                                                                                                                                                                                                                                                                                                                                                    [@b72-cin-11-2012-157]
  SERPINB5 (Maspin)                                                                                                                                                                                                                                                                                                                                                                                                                       [@b91-cin-11-2012-157]
  SMAD4/DPC4                                                                                                                                                                                                                                                                                                                                                                                                                              [@b104-cin-11-2012-157]
  TARBP2                                                                                                                                                                                                                                                                                                                                                                                                                                  [@b85-cin-11-2012-157]
  TIP60                                                                                                                                                                                                                                                                                                                                                                                                                                   [@b68-cin-11-2012-157]
  TNFAIP3                                                                                                                                                                                                                                                                                                                                                                                                                                 [@b103-cin-11-2012-157], [@b55-cin-11-2012-157]
  TP53BP1                                                                                                                                                                                                                                                                                                                                                                                                                                 [@b102-cin-11-2012-157]
  TP63 (TAp63)                                                                                                                                                                                                                                                                                                                                                                                                                            [@b94-cin-11-2012-157]
  XPO5                                                                                                                                                                                                                                                                                                                                                                                                                                    [@b70-cin-11-2012-157]

###### 

Supporting information for [Table 1](#t1-cin-11-2012-157){ref-type="table"}.

  Gene    Location    SNP ID        Allele change   miR ID
  ------- ----------- ------------- --------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ATM     108237837   rs227091      C to T          hsa-miR-3664-3p, hsa-miR-4433-3p, hsa-miR-4768-3p, hsa-miR-512-5p
  CDH1    68867609    rs35942505    C to T          hsa-miR-548ae, hsa-miR-548ah-3p, hsa-miR-548aj-3p, hsa-miR-548am-3p, hsa-miR-548aq-3p, hsa-miR-548x-3p
  DFFB    3800570     rs140704651   C to T          hsa-miR-3664-3p, hsa-miR-4433-3p, hsa-miR-4768-3p, hsa-miR-512-5p
  KIF1B   10367348    rs142468272   C to A          hsa-miR-4435, hsa-miR-4701-5p, hsa-miR-548s, hsa-miR-588
          10367422    rs2004034     G to A          hsa-miR-25-3p, hsa-miR-32-5p, hsa-miR-363-3p, hsa-miR-367-3p, hsa-miR-92a-3p, hsa-miR-92b-3p
          10437247    rs2155760     C to T          hsa-miR-125a-5p, hsa-miR-125b-5p, hsa-miR-4319, hsa-miR-4446-5p, hsa-miR-4732-3p, hsa-miR-4755-5p, hsa-miR-5006-3p, hsa-miR-670
  MDM2    69236548    rs1690917     G to T          hsa-miR-548ac, hsa-miR-548d-3p, hsa-miR-548h-3p, hsa-miR-548z
          69238940    rs184278637   G to A          hsa-miR-3609, hsa-miR-4796-3p, hsa-miR-519a-3p, hsa-miR-519b-3p, hsa-miR-519c-3p, hsa-miR-548ah-5p
  RAD50   131980270   rs75939007    A to G          hsa-miR-199a-3p, hsa-miR-199b-3p, hsa-miR-3129-5p, hsa-miR-936
  RXRA    137330802   rs10119893    G to A          hsa-miR-1254, hsa-miR-1271-3p, hsa-miR-3116, hsa-miR-550a-3-5p, hsa-miR-550a-5p
  SMAD4   48610254    rs146551171   T to C          hsa-miR-142-5p, hsa-miR-548a-5p, hsa-miR-548ab, hsa-miR-548ak, hsa-miR-548am-5p, hsa-miR-548ap-5p, hsa-miR-548aq-5p, hsamiR-548ar-5p, hsa-miR-548as-5p, hsa-miR-548au-5p, hsa-miR-548av-5p, hsa-miR-548b-5p, hsa-miR-548c-5p, hsa-miR-548d-5p, hsa-miR-548h-5p, hsa-miR-548i, hsa-miR-548j, hsa-miR-548k, hsamiR-548o-5p, hsa-miR-548w, hsa-miR-548y, hsa-miR-559, hsa-miR- 5590-3p
  TP53    7574015     rs121912664   G to A          hsa-miR-302a-3p, hsa-miR-302b-3p, hsa-miR-302c-3p, hsa-miR-302d-3p, hsa-miR-302e, hsa-miR-372, hsa-miR-373-3p, hsa-miR-520a-3p, hsa-miR-520b, hsa-miR-520c-3p, hsa-miR- 520d-3p, hsa-miR-520e
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![Effect of SNPs occurring in the 3′UTR of haploinsufficient tumor suppressor genes.\
**Notes:** SNPs in the 3′UTR of haploinsufficient tumor suppressor genes result in creation of new miRNA binding sites as well as deletion of originally existing miRNA binding sites. The 10 SNPs plotted here against their effect on miRNA binding sites contributes to haploinsufficiency, as they bring the polymorphic mRNA under the control of more new microRNAs.](cin-11-2012-157f1){#f1-cin-11-2012-157}

![Interactions among 109 haploinsufficient genes plotted using GeneMANIA plug-in available in Cytoscape.\
**Notes:** Networking analysis of 109 genes by GeneMANIA algorithm revealed different type of interactions between them. Gray circles represent the queried genes, and white circles represent the predicted genes that mediate interactions. Color representations for edges: purple---co-expression, dark blue---physical interaction, green---genetic interaction, light blue---co-localization, and brown---predicted. The network consists of physical, genetic and predicted interactions which can be clearly seen.](cin-11-2012-157f2){#f2-cin-11-2012-157}

![Interactions among 39 haploinsufficient genes that either had miRNA binding site SNPs or were targeted non-specifically by miRNAs carrying miR-SNPs.\
**Notes:** Networking analysis of 39 genes by GeneMANIA algorithm revealed different type of interactions among them. Gray circles represent the queried genes and white circles represent the predicted genes that mediate interactions. Pink circles denote the genes involved in DNA repair and blue circles represent the cell cycle checkpoint genes. Among the queried list, *DIRC2* does not show any type of interaction. Color representations for edges: purple--- co-expression, dark blue---physical interaction, green---genetic interaction, light blue---co-localization, and brown---predicted. The network consists of physical, genetic and predicted interactions which can be clearly seen.](cin-11-2012-157f3){#f3-cin-11-2012-157}

###### 

List of SNPs in the haploinsufficient tumor suppressor genes that created microRNA binding sites in their 3′UTR.

  Gene       Location    SNP ID        Allele change   microRNA binding site created for
  ---------- ----------- ------------- --------------- --------------------------------------------------------------
  ATM        108236469   rs3092834     C to T          hsa-miR-4252
             108237460   rs187308124   C to T          hsa-miR-4428
             108237837   rs227091      C to T          4 microRNAs[\*](#tfn2-cin-11-2012-157){ref-type="table-fn"}
             108238032   rs114847811   C to T          hsa-miR-600
             108239075   rs186644530   A to G          hsa-miR-2117
             108239099   rs191399133   T to C          hsa-miR-4448
             108239463   rs3092852     C to T          hsa-miR-1265
  BAG1       33253621    rs191119067   G to C          hsa-miR-4452, hsa-miR-4680-3p
  CAMTA1     7827003     rs183056496   G to A          hsa-miR-582-3p
             7828815     rs112733335   G to A          hsa-miR-342-3p
  CDH1       68867609    rs35942505    C to T          6 microRNAs[\*](#tfn2-cin-11-2012-157){ref-type="table-fn"}
             68868146    rs140240766   C to A          hsa-miR-427
             68868576    rs9282654     T to G          hsa-miR-129-1-3p, hsa-miR-129-2-3p
             68869062    rs33967108    G to C          hsa-miR-1273a
             68869394    rs146556488   C to A          hsa-miR-369-3p
  CDKN1B     12874056    rs114975362   G to T          hsa-miR-3919
  CHEK1      125525308   rs148807246   A to G          hsa-miR-1184, hsa-miR-1205, hsa-miR-3158-5p
             125545904   rs192805943   G to A          hsa-miR-2964a-3p
  CLU        27454684    rs9331949     A to G          hsa-miR-1283
  CTCF       67672530    rs187258944   G to T          hsa-miR-2276
  DFFB       3800550     rs146888429   G to A          hsa-miR-1227
             3800570     rs140704651   C to T          4 microRNAs[\*](#tfn2-cin-11-2012-157){ref-type="table-fn"}
  DIRC2      122598847   rs150233566   G to C          hsa-miR-4797-5p
             122599452   rs180703954   A to C          hsa-miR-3927, hsa-miR-4451, hsa-miR-4732-5p
  ETV6       12043995    rs183579990   C to G          hsa-miR-3160-3p, hsa-miR-558
             12044403    rs79663578    T to A          hsa-miR-5011-5p
             12045614    rs183305984   G to A          hsa-miR-3690
             12045861    rs72550771    T to C          hsa-miR-4774-5p
  FBXW7      153243322   rs4399968     G to C          hsa-miR-338-3p, hsa-miR-634
  FEN1       61564571    rs141406755   T to C          hsa-miR-3654
  KIF1B      10365509    rs180831292   C to G          hsa-miR-4768-5p
             10365953    rs72640311    T to G          hsa-miR-1972
             10366284    rs115354754   A to C          hsa-miR-3934, hsa-miR-764
             10366763    rs56164683    A to G          hsa-miR-27a-3p, hsa-miR-27b-3p
             10366766    rs187140427   A to T          hsa-miR-376c
             10367056    rs41274464    G to A          hsa-miR-148b-5p, hsa-miR-3168
             10367348    rs142468272   C to A          4 microRNAs[\*](#tfn2-cin-11-2012-157){ref-type="table-fn"}
             10367422    rs2004034     G to A          6 microRNAs[\*](#tfn2-cin-11-2012-157){ref-type="table-fn"}
             10367577    rs143823495   G to T          hsa-miR-4494, hsa-miR-4499
             10367816    rs145128126   A to T          hsa-miR-3941, hsa-miR-466, hsa-miR-4672
             10437247    rs2155760     C to T          8 microRNAs[\*](#tfn2-cin-11-2012-157){ref-type="table-fn"}
             10437802    rs4240913     G to A          hsa-miR-645
             10438336    rs189264558   A to G          hsa-miR-516a-3p, hsa-miR-516b-3p
             10439362    rs186201500   A to C          hsa-miR-199a-5p, hsa-miR-199b-5p, hsa-miR-644a
             10439538    rs184232081   G to A          hsa-miR-4425
             10440756    rs192312673   C to T          hsa-miR-4797-5p
             10440757    rs148005450   G to A          hsa-miR-4534
  KLF5       73650341    rs117651109   C to T          hsa-miR-5579-5p
  MDM2       69235650    rs144972734   A to G          hsa-miR-671-5p
             69236143    rs190072365   C to T          hsa-miR-934
             69236269    rs142063414   G to A          hsa-miR-3198, hsa-miR-4309
             69236548    rs1690917     G to T          4 microRNAs[\*](#tfn2-cin-11-2012-157){ref-type="table-fn"}
             69237299    rs183077346   T to A          hsa-miR-889
             69237446    rs150137388   A to G          hsa-miR-9-3p
             69238249    rs141938174   C to T          hsa-miR-4705
             69238568    rs148584832   G to A          hsa-miR-4522
             69238940    rs184278637   G to A          6 microRNAs
  PAX5       36839029    rs184505592   G to C          hsa-miR-4520a-3p
  PPARA      46631658    rs4253801     A to G          hsa-miR-4709-5p
             46631718    rs183307497   A to G          hsa-miR-5095, hsa-miR-600
             46631838    rs188241700   T to G          hsa-miR-1470, hsa-miR-4287, hsa-miR-4685-3p
             46632587    rs9615264     G to A          hsa-miR-1231
             46632932    rs181140325   T to A          hsa-miR-4277
             46633120    rs78922364    G to C          hsa-miR-499b-5p
             46633549    rs115356860   C to T          hsa-miR-892b
             46633564    rs148478205   C to T          hsa-miR-4252
             46634352    rs184920139   G to A          hsa-miR-301a-5p
             46634514    rs41418950    C to T          hsa-miR-936
             46635061    rs41403648    G to A          hsa-miR-3944-5p, hsa-miR-5094
             46636623    rs56180992    G to A          hsa-miR-515-5p, hsa-miR-519e-5p
             46637760    rs181781384   A to G          hsa-miR-4733-3p
             46638155    rs1055658     G to C          hsa-miR-744-5p
             46638209    rs79700435    G to A          hsa-miR-3191-5p, hsa-miR-518c-5p
             46639161    rs187605878   A to G          hsa-miR-3157-3p
             46639611    rs117317496   G to C          hsa-miR-5584-5p
  PTCH1      98205709    rs28413010    A to T          hsa-miR-126-5p, hsa-miR-4795-3p
             98206995    rs41316950    C to G          hsa-miR-4690-3p, hsa-miR-5685
  PTEN       89725452    rs3895069     T to G          hsa-miR-5003-5p
             89726622    rs79395513    C to A          hsa-miR-651
             89726726    rs180953647   C to T          hsa-miR-510
  RAD50      131980172   rs146790944   A to G          hsa-miR-300, hsa-miR-381
             131980267   rs139468574   A to G          hsa-miR-4524a-5p, hsa-miR-4524b-5p
             131980270   rs75939007    A to G          4 microRNAs[\*](#tfn2-cin-11-2012-157){ref-type="table-fn"}
  RB1        49054521    rs187845274   T to A          hsa-miR-4638-3p
             49054779    rs150194261   T to C          hsa-miR-145-5p, hsa-miR-5195-3p
             49055241    rs192758219   G to T          hsa-miR-1323, hsa-miR-548o-3p
  RXRA       137328831   rs1805346     G to A          hsa-miR-3688-3p
             137328936   rs189590058   C to T          hsa-miR-4738-3p
             137329304   rs4240711     G to A          hsa-miR-3184-3p
             137329411   rs34449651    G to C          hsa-miR-3919
             137329652   rs35283205    G to C          hsa-miR-4685-5p
             137330306   rs180869938   T to C          hsa-miR-1908, hsa-miR-663a
             137330727   rs17847916    C to T          hsa-miR-4721
             137330802   rs10119893    G to A          5 microRNAs[\*](#tfn2-cin-11-2012-157){ref-type="table-fn"}
             137330980   rs139882385   T to C          hsa-miR-518a-5p, hsa-miR-527
             137331443   rs139749844   G to A          hsa-miR-3170, hsa-miR-5572
             137331999   rs11103561    G to A          hsa-miR-4722-3p, hsa-miR-4769-3p
             137332362   rs187745805   G to A          hsa-miR-5010-3p, hsa-miR-599
             137332378   rs137912651   G to C          hsa-miR-301a-5p
  SERPINB5   61171674    rs112795011   A to C          hsa-miR-4535, hsa-miR-4776-5p
  SMAD4      48605247    rs28403611    A to G          hsa-miR-552
             48605297    rs191822473   G to A          hsa-miR-656
             48605643    rs183984903   A to G          hsa-miR-5095
             48607107    rs189547031   G to C          hsa-miR-5584-5p
             48607497    rs191637734   A to T          hsa-miR-421, hsa-miR-4272
             48608123    rs191317135   C to T          hsa-miR-3163
             48609056    rs150556996   G to T          hsa-miR-4496
             48609588    rs112739300   C to T          hsa-miR-297, hsa-miR-3149, hsa-miR-675-3p
             48609716    rs184516281   T to C          hsa-miR-584-3p
             48609918    rs145596898   G to A          hsa-miR-4694-3p
             48610254    rs146551171   T to C          23 microRNAs[\*](#tfn2-cin-11-2012-157){ref-type="table-fn"}
             48610822    rs12954419    T to A          hsa-miR-5696
             48610844    rs181250637   G to C          hsa-miR-636
             48611357    rs183472455   C to T          hsa-miR-371b-5p, hsa-miR-373-5p, hsa-miR-616-5p
  SOX9       70121452    rs74999341    T to C          hsa-miR-4759
             70121525    rs185467299   C to T          hsa-miR-4514, hsa-miR-4692, hsa-miR-4742-5p
  TNFAIP3    138202555   rs140042278   G to T          hsa-miR-208a, hsa-miR-208b, hsa-miR-499a-5p
             138202864   rs76710415    A to C          hsa-miR-4533
             138203096   rs73778206    T to C          hsa-miR-223-3p
             138203386   rs191520762   T to G          hsa-miR-4772-3p
             138203884   rs73778207    G to A          hsa-miR-96-3p
  TP53       7572039     rs35659787    G to A          hsa-miR-516b-5p, hsa-miR-518c-5p
             7574010     rs17882252    G to A          hsa-miR-127-5p
             7574015     rs121912664   G to A          12 microRNAs[\*](#tfn2-cin-11-2012-157){ref-type="table-fn"}
  VHL        10191771    rs34362094    C to T          hsa-miR-5579-5p
             10192172    rs190102073   A to G          hsa-miR-4448
             10193434    rs115303528   G to A          hsa-miR-592, hsa-miR-599
             10193848    rs145666034   G to A          hsa-miR-3545-3p
             10194195    rs187719061   A to G          hsa-miR-371a-5p

**Notes:** This table enlists the 129 SNPs that create new miRNA binding sites in the 3′UTR of their respective haploinsufficient tumor suppressor gene. Table compiled from the data provided by PolymiRTS database.

For convenience these microRNAs are not indicated in the table, and for details the reader is referred to [Supplement 2](#s2-cin-11-2012-157){ref-type="supplementary-material"}.

###### 

SNPs in miR seed and their new target haploinsufficient genes.

  miR ID          SNP ID        miR seed        Allele   Haploinsufficient gene targets
  --------------- ------------- --------------- -------- ------------------------------------------------------------
  hsa-mir-125a    rs12975333    CCCUGA\[G/U\]   G/T      ATM, MSH2
  hsa-miR-1268    rs28599926    GGGC\[G/A\]UG   G/A      ATM, PAX5, PPARA, PTEN, NBN
  hsa-miR-1469    rs116596918   UCGGC\[G/C\]C   C/G      DDB2, FOXP1
  hsa-miR-3610    rs112072631   AAUCGG\[A/C\]   C/A      SERPINB5, SMAD4
  hsa-miR-3615    rs112977728   CU\[C/U\]UCGG   C/T      RAD50, NBN, TP53BP2
  hsa-miR-3618    rs12159555    GU\[C/G\]UACA   C/G      DFFB, PPARA, SMAD4, FOXP1
  hsa-miR-3689b   rs116838571   GUGAU\[A/U\]U   T/A      CDH1, CDKN1B, FBXW7, RB1, VHL, BRCA2, ROR2, TP53BP2, YWHAE
  hsa-miR-379     rs61991156    GGUAG\[A/G\]C   A/G      CAMTA1, DFFB, TNFAIP3, VHL
  hsa-miR-4257    rs74743733    CAGA\[G/A\]GU   A/G      CHEK1, DIRC2, ETV6, PAX5, SOX9
  hsa-miR-4284    rs11973069    GGCUCA\[C/U\]   C/T      BAG1, ETV6, TP53BP2
  hsa-miR-4305    rs4636784     CUA\[G/C\]ACA   G/C      CDH1, DFFB, FBXW7, KIF1B, PTEN, SMAD4, FOXP1, NBN, MDM2
  hsa-miR-4322    rs114399468   UGUGG\[G/A\]C   A/G      CHEK1, KIF1B, PTEN, RAD50, SERPINB5
  hsa-miR-557     rs78825966    UUUGCA\[C/U\]   C/T      BAG1, CHEK1, BRCA2, RPL37A, KLF5
  hsa-miR-585     rs62376935    GG\[G/A\]CGUA   G/A      BAG1, KIF1B, NBN, TP53BP2
  hsa-miR-605     rs113212828   \[A/G\]AAUCCC   A/G      RAD50, RB1, VHL, MSH2
  hsa-miR-642a    rs78902025    UCCC\[U/G\]CU   G/T      ATM, PPARA, SERPINB5
  hsa-miR-642b    rs111664333   GA\[C/U\]ACAU   T/C      ATM, RAD50, SMAD4, NBN, TP53BP2
  hsa-miR-936     rs79924817    C\[A/G\]GUAGA   G/A      ATM, BAG1, PPARA, RAD50, XPO5
  hsa-miR-938     rs12416605    \[G/A\]CCCUUA   G/A      BAG1, PPARA, PTEN, SMAD4, SOX9, TNFAIP3, XPO5, MDM2

**Notes:** This table represents the miR-SNPs that render microRNAs to bind with non-specificity to haploinsufficient tumor suppressor genes. Table compiled from the data extracted from PolymiRTS database.
